(AOF) – Patients should take the weight loss drug Wegovy much longer than older treatments. This was declared yesterday by Lars Fruergaard Jorgensen, general director of the Danish laboratory Novo Nordisk (+0.82% to 729.00 Norwegian crowns), of which Wegowy is the flagship product, during the JPMorgan Healthcare Conference organized in San Francisco. According to him, the effects observed by patients after taking this medication would encourage them to continue their treatment. It is thanks to this product that the group must have become the leading European capitalization.
Mr. Jorgensen added that his group currently cares for 14 million diabetic and obese patients worldwide, and said there is room in the obesity market for injectable and oral treatments.
Reuters cites a December 2023 study that found 40% of patients who filled a prescription for Wegovy in 2021 or 2022 were still taking it a year later, more than three times the compliance rate found for older drugs.
Wegovy and its rival Eli Lilly’s Zepbound belong to the class of drugs called GLP-1 agonists, originally developed for diabetes, which in addition to controlling blood sugar levels, suppress appetite. According to JPMorgan, the market for GLP-1 weight loss drugs is expected to be worth more than $44 billion in 2030 compared to $1.5 billion expected this year.
In order to meet strong demand, the Danish group has announced significant investments. Regarding France, Novo Nordisk announced at the end of November an investment of 2.1 billion euros starting this year in order to expand its Chartres site focused on serious chronic diseases
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
